I am using JunctionSeq to test for differential exon and splice junction usage in a paired-end RNA-seq experiment and have a question about how the package computes effect sizes using linear contrasts.
Experimental design: my main condition variable is a drug treatment with three levels: vehicle, acute drug, chronic drug. However, to acquire the RNA I use an affinity purification that generates two biochemical fractions: "input" and "bound" RNA. Input is RNA from the whole tissue before affinity purification, bound is RNA enriched during affinity purification. As a note, I have enough biological replicates to calculate the dispersion.
My question: I am interested in the drug effect, but specifically as it co-varies with the biochemical fraction as there is variation in the dissection and biochemistry that is captured by the fraction variable. Thus, in my final model, I have drug treatment (condition) and fraction (co-variate). I have incorporated the co-variate into my GLM test formulas exactly as described in Section 8.2 of the user manual (p. 40-41, Advanced Generalized Linear Modelling). substituting my fraction variable for the Smoker variable. In Section 7.5 of the user manual (p. 37, Parameter Estimation), it states that linear contrasts using the Beta parameter estimates are used to the calculate the effect size (fold-change), and that co-variates can be incorporated during the process. So my main question is the following: By default, if I run a JunctionSeq analysis with the appropriate test.formulae, are all parameter estimates used in the calculation of fold-change?
Thanks for your thoughtful answer! I'll experiment more with model matrices and R's glm to prove it to myself.